Metoclopramide & Gastroparesis

The FDA has approved Gimoti (Evoke), a nasal spray formulation of the dopamine-2 (D2) receptor antagonist metoclopramide, for relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Metoclopramide (Reglan, and generics) has been available for years in conventional and orally-disintegrating tablets and in an injectable formulation. It is the only drug that is FDA-approved for treatment of diabetic gastroparesis.
Asha & Khalil 2019

Gastroparesis treatment with Metoclopramide (10 mg, 10–15 min before a meal, preferably liquid formulation).
Bekkelund et al. 2019

Clinical guidelines recommend metoclopramide beginning with 5 mg 3 times a day 30 min before meals with a maximum dose of 40 mg a day
Camilleri et al. 2013 Am J Gastroenterol 108(1): p. 18–37

Metoclopramide promotes gut motility b…